Summary: The weight loss drug, Zepbound, faces immense competition and may lose its battle once
Summary: Eli Lily has the highest market capitalization of any Healthcare company, but its low
Summary: Eli Lilly’s anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval
Summary: Eli Lilly has received FDA approval for ‘Zepbound’ as a GLP-1 weight loss drug
Summary: Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market
Summary: Valuation and fundamentals always matter, driving 97% of long-term stock returns. The market is
Summary: Eli Lilly is expected to receive FDA approval for tirzepatide, an obesity medication, and
Summary: LLY may have found the next blockbuster drug, potentially exceeding ABBV’s Humira with FY2022
Summary: Eli Lilly has acquired POINT Biopharma Global in a $1.4 billion all-cash deal. POINT
Summary: Eli Lilly’s acquisition of POINT Biopharma Global strategically boosts its portfolio in radiopharmaceuticals, with